Can Old Drugs Learn New Tricks? Achieving Registration and Public Subsidy Listing for Off-patent Medicines with Novel Therapeutic Applications
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
With the increasing costs of drug development, repurposing of low-cost medicines for new indications has never been more important. However, there are multiple barriers to repurposing, particularly for off-patent medicines, and limited incentives for the pharmaceutical industry to sponsor registration and public subsidy listing. Here, we explore these barriers and their consequences and provide examples of successful repurposing strategies.
Citing Articles
Siefried K, Acheson L, Clifford B, Moller C, Brett J, Christmass M BMJ Open. 2025; 15(2):e092032.
PMID: 39920060 PMC: 11808914. DOI: 10.1136/bmjopen-2024-092032.
References
1.
Lipworth W, Ho K, Kerridge I, Day R
. Drug policy at the margins: the case of growth hormone replacement for adults with severe growth hormone deficiency. Med J Aust. 2012; 197(4):204-5.
DOI: 10.5694/mja11.11572.
View
2.
Bahji A, Vazquez G, Zarate Jr C
. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2020; 278:542-555.
PMC: 7704936.
DOI: 10.1016/j.jad.2020.09.071.
View
3.
Lipworth W, Ambler G, Burt M, Fairchild J, Inder W, Werther G
. A will and a way to fund medicines for rare diseases: the story of human growth hormone replacement for adults with growth hormone deficiency. Intern Med J. 2018; 48(8):999-1002.
DOI: 10.1111/imj.13943.
View
4.
Lipworth W, Wodak A, Haber P, Day R
. Why is disulfiram not on the PBS?. Med J Aust. 2011; 195(7):371-2.
DOI: 10.5694/mja11.10708.
View
5.
Pushpakom S, Iorio F, Eyers P, Jane Escott K, Hopper S, Wells A
. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018; 18(1):41-58.
DOI: 10.1038/nrd.2018.168.
View